Abstract
The short- and long-term outcomes of patients treated with class I antiarrhythmic drugs were studied. A total of 968 patients who began class I antiarrhythmic therapy in our hospital were followed up for a mean of 13 ± 8 months. Discontinuation rates were similar for the entire group of patients during short-term therapy (52%) and long-term therapy (50%). During short-term therapy, 28% of patients stopped treatment because of side effects, and 21% of patients discontinued treatment because of ineffectiveness. Discontinuation rates during short-term therapy were significantly lower with encainide, flecainide, and procainamide than with the other agents (disopyramide, mexiletine, qunidine gluconate, quinidine sulfate, and tocainide) (P <0.05). However, encainide, flecainide, and procainamide were associated with a higher incidence of side effects necessitating discontinuation in the long-term study. Side effects during long-term therapy accounted for 27% of discontinuations, while loss of efficacy accounted for only 6%. Discontinuation rates were significantly lower with mexiletine, quinidine sulfate, and tocainide than with the other agents during long-term therapy (P <0.05). The discontinuation rate with quinidine gluconate was significantly less than that with quinidine sulfate. All antiarrhythmic agents possess a substantial potential for toxicity. Short-term response and tolerance to class I antiarrhythmics do not predict the ultimate response to therapy. Thus patients receiving class I antiarrhythmic therapy must be monitored for the duration of treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 730-738 |
| Number of pages | 9 |
| Journal | Current Therapeutic Research - Clinical and Experimental |
| Volume | 51 |
| Issue number | 5 |
| State | Published - 1992 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Medicine(all)
Cite this
Adverse reactions during acute and chronic class I antiarrhythmic therapy. / Hilleman, Daniel E.; Mohiuddin, Syed M.; Gannon, J. M.
In: Current Therapeutic Research - Clinical and Experimental, Vol. 51, No. 5, 1992, p. 730-738.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Adverse reactions during acute and chronic class I antiarrhythmic therapy
AU - Hilleman, Daniel E.
AU - Mohiuddin, Syed M.
AU - Gannon, J. M.
PY - 1992
Y1 - 1992
N2 - The short- and long-term outcomes of patients treated with class I antiarrhythmic drugs were studied. A total of 968 patients who began class I antiarrhythmic therapy in our hospital were followed up for a mean of 13 ± 8 months. Discontinuation rates were similar for the entire group of patients during short-term therapy (52%) and long-term therapy (50%). During short-term therapy, 28% of patients stopped treatment because of side effects, and 21% of patients discontinued treatment because of ineffectiveness. Discontinuation rates during short-term therapy were significantly lower with encainide, flecainide, and procainamide than with the other agents (disopyramide, mexiletine, qunidine gluconate, quinidine sulfate, and tocainide) (P <0.05). However, encainide, flecainide, and procainamide were associated with a higher incidence of side effects necessitating discontinuation in the long-term study. Side effects during long-term therapy accounted for 27% of discontinuations, while loss of efficacy accounted for only 6%. Discontinuation rates were significantly lower with mexiletine, quinidine sulfate, and tocainide than with the other agents during long-term therapy (P <0.05). The discontinuation rate with quinidine gluconate was significantly less than that with quinidine sulfate. All antiarrhythmic agents possess a substantial potential for toxicity. Short-term response and tolerance to class I antiarrhythmics do not predict the ultimate response to therapy. Thus patients receiving class I antiarrhythmic therapy must be monitored for the duration of treatment.
AB - The short- and long-term outcomes of patients treated with class I antiarrhythmic drugs were studied. A total of 968 patients who began class I antiarrhythmic therapy in our hospital were followed up for a mean of 13 ± 8 months. Discontinuation rates were similar for the entire group of patients during short-term therapy (52%) and long-term therapy (50%). During short-term therapy, 28% of patients stopped treatment because of side effects, and 21% of patients discontinued treatment because of ineffectiveness. Discontinuation rates during short-term therapy were significantly lower with encainide, flecainide, and procainamide than with the other agents (disopyramide, mexiletine, qunidine gluconate, quinidine sulfate, and tocainide) (P <0.05). However, encainide, flecainide, and procainamide were associated with a higher incidence of side effects necessitating discontinuation in the long-term study. Side effects during long-term therapy accounted for 27% of discontinuations, while loss of efficacy accounted for only 6%. Discontinuation rates were significantly lower with mexiletine, quinidine sulfate, and tocainide than with the other agents during long-term therapy (P <0.05). The discontinuation rate with quinidine gluconate was significantly less than that with quinidine sulfate. All antiarrhythmic agents possess a substantial potential for toxicity. Short-term response and tolerance to class I antiarrhythmics do not predict the ultimate response to therapy. Thus patients receiving class I antiarrhythmic therapy must be monitored for the duration of treatment.
UR - http://www.scopus.com/inward/record.url?scp=0026600141&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026600141&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0026600141
VL - 51
SP - 730
EP - 738
JO - Current Therapeutic Research
JF - Current Therapeutic Research
SN - 0011-393X
IS - 5
ER -